VisMederi Holding

Improving human health

Vismederi Holding

Vismederi Holding is the company that holds a qualified share of the companies that are part of the VisMederi Group. The Group of Vismederi Holding operates in various business areas all related to Research and Innovation in the fields of Public Health, Life Sciences and Biotechnologies and is composed of VisMederi Srl, VisMederi Research Srl, VisMederi Life Sciences Srl, VisMederi Textyle Srl, VisMederi Pharma Srl, ETHS – Education and Training for Health Sciences Srl with single shareholder, Accurange Srl.

Vismederi Holding
0Mln €

Revenues

0

Employees 

0Paesi

Global Partnerships

Vismederi Holding: last news

All the news of the group

Jan 25 2024

Our manuscript “#CEPI Centralized Laboratory Network: a qualification analysis” has been published in The Lancet Microbe Online

Our manuscript "#CEPI Centralized Laboratory Network: a qualification analysis" has been published in The Lancet Microbe Online. This publication...
Jan 18 2024

New Research Highlights the Importance of Vaccinations in Leukemia Patients

VisMederi is excited to share a significant breakthrough in medical research conducted in collaboration with Landspítali University of Reykjavík,...
Nov 23 2023

Making Strides in Global Health: VisMederi at the World Bio Summit 2023!

VisMederi, represented by the Founder and CSO Prof. Emanuele Montomoli, played a pivotal role at the esteemed World Bio Summit 2023 in Seoul. This...
Nov 23 2023

VisMederi reaffirms its position as a “Growth Leader”

The Siena-based business ranks second in the "Pharmaceuticals and Biotechnology" category and 84th overall....
Nov 21 2023

GBA Roadshow 2023

Embarking on a journey of growth and opportunity, VisMederi's Chief Financial Officer, Simone Paletti, is participating in the esteemed GBA Roadshow...
Nov 21 2023

Project Leader Silvia Grappi represented VisMederi at the 11th EDTCP meeting in Paris

The biannual EDCTP Forum offered a worldwide venue for the presentation and discussion of clinical research for anybody concerned in the fight...
Oct 25 2023

VisMederi Foundation with “Ragazzi del ‘53” in support of “Le Bollicine” Association

That of the "Ragazzi del '53" is an adventure born in 1953 from the will of some young adults in their 30s who were entering, according to the...
Aug 14 2023

Another remarkable milestone in our journey of scientific collaboration

We're thrilled to share another remarkable milestone in our journey of scientific collaboration. Our latest article,” "Characterization of...
Jul 23 2023

VisMederi Foundation: Continuing its Commitment to Social Welfare by Supporting Piccolo Principe and Danilo Nannini Foundation

The VisMederi Foundation demonstrates its commitment to the most vulnerable groups, strengthening its ties with the Siena territory and actively...
Jul 17 2023

VisMederi Receives Prestigious Certificate from The Coalition for Epidemic Preparedness Innovations (CEPI)

We are delighted to share the exciting news that VisMederi has been honored with a prestigious certificate from The Coalition for Epidemic...

Where we

are

 

 

 

 

 

 

The

founder

Emanuele Montomoli is Full Professor of Hygiene and Public Health at the University of Siena, Italy. He received his BSc and MSc in Life Sciences from the University of Siena, Italy in 1997 and he earned his MBiochem in 2001.

Comments Box SVG iconsUsed for the like, share, comment, and reaction icons

Exciting news from our partners at Invivyd! They received emergency use authorization in the United States from the FDA for their investigational monoclonal antibody, aimed at the pre-exposure prophylaxis (prevention) of COVID-19 in certain authorized populations. A significant step forward in the fight against COVID-19, providing a new therapeutic option for those at risk.

Since 2020, VisMederi has been proud to collaborate with Invivyd. For this project VisMederi’s team has conducted escape mutation studies through serial passaging of authentic SARS-COV-2 variants in the presence of Invivyd’s antibodies. This critical work assesses the ability of Invivyd’s product candidates to resist viral escape, helping better characterize this innovative treatment. For more details on this important therapeutic option, read the full press release here: lnkd.in/eU53rF9W.

Together, we're making strides towards a safer, COVID-19 free world.

#Partnership #InnovationInHealthcare #COVID19Prevention #VisMederigroup #invivyd

*************

Novità importanti dai nostri partner di Invivyd! Hanno ricevuto l'autorizzazione all'uso di emergenza negli Stati Uniti dalla FDA per il loro anticorpo monoclonale sperimentale, mirato alla profilassi pre-esposizione (prevenzione) di COVID-19 in certe popolazioni autorizzate. Un passo significativo nella lotta contro il COVID-19, fornendo una nuova opzione terapeutica per coloro che sono a rischio.

Dal 2020, VisMederi è orgogliosa di collaborare con Invivyd.

Per maggiori dettagli su questa importante opzione terapeutica, leggi il comunicato stampa completo qui: lnkd.in/eU53rF9W.

Insieme, stiamo facendo passi avanti verso un mondo più sicuro, libero da COVID-19.

#Partnership #InnovazioneNellaSanità #PrevenzioneCOVID19 #VisMederi #Invivyd
... See MoreSee Less

VisMederi Group attended the World Vaccine Congress in Washington, D.C., acknowledged as the most significant and longstanding event dedicated to the field of vaccines. This congress served as an exceptional platform for engaging with leaders across the entire vaccine industry's value chain.

During the congress, our Chief Development Officer, Alessandro Manenti, delivered an insightful presentation on "Vaccine Evaluation: Serological Assays for Viruses and Respiratory Diseases," sharing valuable knowledge and the latest developments in the field.

We were proud to join forces with top professionals from around the world, initiating new collaborations and strengthening existing ones.

#VisMederi #vaccines #VaccineSaveLives #researchanddevelopment

°°°°°°

VisMederi Group ha partecipato al "World Vaccine Congress in Washington, D.C.", riconosciuto come l'evento più significativo e di lunga data dedicato al campo dei vaccini.

Durante il congresso, il Chief Development Officer, Alessandro Manenti, ha tenuto una presentazione su "Valutazione dei Vaccini: Assaggi Sierologici per Virus e Malattie Respiratorie," condividendo conoscenze preziose e gli ultimi sviluppi nel campo.

Un'opportunità per unire le forze con professionisti di spicco da tutto il mondo, avviando nuove collaborazioni e rafforzando quelle esistenti.

#VisMederiGroup #vaccini #ricerca #sviluppo
... See MoreSee Less

VisMederi Group attended the World Vaccine Congress in Washington, D.C., acknowledged as the most significant and longstanding event dedicated to the field of vaccines. This congress served as an exceptional platform for engaging with leaders across the entire vaccine industrys value chain.

During the congress, our Chief Development Officer, Alessandro Manenti, delivered an insightful presentation on Vaccine Evaluation: Serological Assays for Viruses and Respiratory Diseases, sharing valuable knowledge and the latest developments in the field.

We were proud to join forces with top professionals from around the world, initiating new collaborations and strengthening existing ones. 

#VisMederi  #vaccines #VaccineSaveLives #researchanddevelopment 

°°°°°°

VisMederi Group ha partecipato al World Vaccine Congress in Washington, D.C., riconosciuto come levento più significativo e di lunga data dedicato al campo dei vaccini.

Durante il congresso, il Chief Development Officer, Alessandro Manenti, ha tenuto una presentazione su Valutazione dei Vaccini: Assaggi Sierologici per Virus e Malattie Respiratorie, condividendo conoscenze preziose e gli ultimi sviluppi nel campo.

Unopportunità per unire le forze con professionisti di spicco da tutto il mondo, avviando nuove collaborazioni e rafforzando quelle esistenti.

#VisMederiGroup #vaccini #ricerca #sviluppoImage attachmentImage attachment

VisMederi has achieved a distinguished place in the prestigious FT 1000 ranking by the Financial Times, securing the 346th position among Europe's fastest-growing companies! This honor not only signifies our success and growth in the research and development field but also our unwavering commitment to innovation and excellence.

Our CSO, Emanuele Montomoli, has expressed his deep gratitude for this achievement, highlighting the hard work and dedication of the entire VisMederi team.

In a world where business dynamics rapidly change, often moving away from their origins for various strategic reasons, VisMederi proudly stands out as a stronghold of Sienese identity.

This accomplishment is a significant moment for us, reinforcing our role as a leader dedicated to shaping the future through innovation and a deep connection to our roots.

#Vismederigroup #FT1000 #Innovation #ResearchAndDevelopment #SieneseExcellence #ShapingTheFuture
°°°°°°°°°°°°

VisMederi ha ottenuto un posto di rilievo nell'ambito ranking FT 1000 del Financial Times, classificandosi al 346° posto tra le aziende europee a più rapida crescita!
Questo riconoscimento non è solo un segno del nostro successo e della nostra crescita nel settore della ricerca e sviluppo ma sottolinea anche il nostro impegno verso l'innovazione e l'eccellenza.

Il CSO, Emanuele Montomoli, ha espresso la sua gratitudine per questo risultato, riconoscendo il duro lavoro e la dedizione di tutto il team VisMederi.

In un mondo dove le dinamiche aziendali si evolvono rapidamente, spesso allontanandosi dai loro luoghi di origine per diversi motivi strategici, VisMederi si distingue orgogliosamente come un baluardo di identità senese.

#VisMederi #Innovazione #RicercaESviluppo #OrgoglioSenese #Crescita #Successo
... See MoreSee Less

VisMederi has achieved a distinguished place in the prestigious FT 1000 ranking by the Financial Times, securing the 346th position among Europes fastest-growing companies! This honor not only signifies our success and growth in the research and development field but also our unwavering commitment to innovation and excellence.

Our CSO, Emanuele Montomoli, has expressed his deep gratitude for this achievement, highlighting the hard work and dedication of the entire VisMederi team.

In a world where business dynamics rapidly change, often moving away from their origins for various strategic reasons, VisMederi proudly stands out as a stronghold of Sienese identity.

This accomplishment is a significant moment for us, reinforcing our role as a leader dedicated to shaping the future through innovation and a deep connection to our roots.

#Vismederigroup #FT1000 #Innovation #ResearchAndDevelopment #SieneseExcellence #ShapingTheFuture
°°°°°°°°°°°°

VisMederi ha ottenuto un posto di rilievo nellambito ranking FT 1000 del Financial Times, classificandosi al 346° posto tra le aziende europee a più rapida crescita! 
Questo riconoscimento non è solo un segno del nostro successo e della nostra crescita nel settore della ricerca e sviluppo ma sottolinea anche il nostro impegno verso linnovazione e leccellenza.

Il CSO, Emanuele Montomoli, ha espresso la sua gratitudine per questo risultato, riconoscendo il duro lavoro e la dedizione di tutto il team VisMederi. 

In un mondo dove le dinamiche aziendali si evolvono rapidamente, spesso allontanandosi dai loro luoghi di origine per diversi motivi strategici, VisMederi si distingue orgogliosamente come un baluardo di identità senese.

#VisMederi #Innovazione #RicercaESviluppo #OrgoglioSenese #Crescita #SuccessoImage attachment

Elisa Mennitto, Chief Facilities and Lab Officer, represented VisMederi at the University of Siena's prestigious event "USiena Game".

Addressing over 90 students from various schools, Elisa showcased the innovative spirit and cutting-edge research at the heart of VisMederi.

The USiena Game 2024 brought together bright minds and passionate learners, and we were honored to be part of their journey. A special thank you to all the students who participated and showed their enthusiasm for science and discovery and to the University of Siena for organizing such an innovative event.

#VisMederi #USienaGame2024 #Innovation #ScienceEducation
°°°°°°°°°

Elisa Mennitto, Chief Facilities and Lab Officer, ha rappresentato VisMederi all'importante evento dell'Università di Siena "Usiena Game".

Rivolgendosi a oltre 90 studenti di varie scuole, Elisa ha messo in luce lo spirito innovativo e la ricerca all'avanguardia che sono al cuore di VisMederi.

L'USiena Game 2024 ha riunito tante giovani menti brillanti ed è stato un onore fare parte del loro percorso. Un ringraziamento speciale a tutti gli studenti che hanno partecipato e mostrato il loro entusiasmo per la scienza e la scoperta e all'Università degli Studi di Siena per aver organizzato l'evento.

Università degli Studi di Siena

#VisMederiGroup #Innovazione #EducazioneScientifica
... See MoreSee Less

Elisa Mennitto, Chief Facilities and Lab Officer, represented VisMederi at the University of Sienas prestigious event USiena Game.

Addressing over 90 students from various schools, Elisa showcased the innovative spirit and cutting-edge research at the heart of VisMederi.

The USiena Game 2024 brought together bright minds and passionate learners, and we were honored to be part of their journey. A special thank you to all the students who participated and showed their enthusiasm for science and discovery and to the University of Siena for organizing such an innovative event.

#VisMederi #USienaGame2024 #Innovation #ScienceEducation
°°°°°°°°°

Elisa Mennitto, Chief Facilities and Lab Officer, ha rappresentato VisMederi allimportante evento dellUniversità di Siena Usiena Game.

Rivolgendosi a oltre 90 studenti di varie scuole, Elisa ha messo in luce lo spirito innovativo e la ricerca allavanguardia che sono al cuore di VisMederi.

LUSiena Game 2024 ha riunito tante giovani menti brillanti ed è stato un onore fare parte del loro percorso. Un ringraziamento speciale a tutti gli studenti che hanno partecipato e mostrato il loro entusiasmo per la scienza e la scoperta e allUniversità degli Studi di Siena per aver organizzato levento.

Università degli Studi di Siena

#VisMederiGroup  #Innovazione #EducazioneScientificaImage attachmentImage attachment
Load more